Oracle Launches AI Agents for Clinical Trial Teams
By Clinical Research News Staff
November 18, 2026 | Oracle today announced Oracle Life Sciences AI Agents for clinical trial operations. By bringing together insights from Oracle Life Sciences applications and supported third-party data sources, the agents are designed to help clinical trial teams identify operational issues, recommend appropriate actions for review and approval, and coordinate responses across clinical development workflows. According to Oracle, an agent can monitor study performance, likely drivers of KPI variances, and recommend operational actions that follow trial protocol.
Oracle Life Sciences AI Agents focus on portfolio monitoring, trial planning, and trial conduct. Planned enhancements are intended to extend AI-assisted capabilities into clinical development domains, including clinical data management, post-trial analytics, trial design, and post-market workflows. The new AI Agents are designed to operate with human oversight, with humans responsible for reviewing recommendations and approving proposed actions before execution.
“Clinical development requires organizations to coordinate complex operational activity across studies, applications, data, and teams,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences in the announcement. “We are bringing AI-assisted intelligence into clinical trial operations to help organizations to monitor performance, identify emerging risks, and coordinate responses across the trial lifecycle. By combining Oracle’s Life Sciences applications, AI-assisted capabilities, connected data services, on a secure, scalable cloud infrastructure, we are helping organizations coordinate clinical research workflows and operational decisions across their clinical trial environments.”



Leave a comment